Business
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights Significant Disease Burden and Unmet Need Among Adults with PKP2-associated ARVC Data Readouts for TN-201 and TN-401 Clinical Programs On Track for the Second Half of 2025 Cash Runway Extended into Second Half of 2026 SOUTH SAN FRANCISCO, Calif., M
About this update from Tenaya Therapeutics, Inc.
[{"type":"image","alt":"Tenaya Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Tenaya Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QJk0bj30LJ12tZdOHYdVGw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6","width":300,"height":108}},"lazy":false},{"type":"text","content":"Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification","length":193,"tagName":"p"},{"type":"text","content":"RIDGE Natural History and Seroprevalence Study Highlights Significant Disease Burden and Unmet Need Among Adults with PKP2-associated ARVC","length":138,"tagName":"p"},{"type":"text","content":"Data Readouts for TN-201 and TN-401 Clinical Programs On Track for the Second Half of 2025","length":95,"tagName":"p"},{"type":"text","content":"Cash Runway Extended into Second Half of 2026","length":45,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.","length":390,"tagName":"p"},{"type":"text","content":"“2025 is off to a strong start for Tenaya as we delivered positive data from our MyPEAK-1 clinical trial evaluating TN-201 for the potential treatment of MYBPC3-associated HCM, shared new findings from the RIDGE natural history study of adults with PKP2-associated ARVC, and extended our cash runway into the second half of 2026,” said Faraz Ali, Chief Executive Officer of Tenaya. “We are pleased to report that patient enrollment is on track for both the MyPEAK-1 study for TN-201 and the RIDGE-1 study for TN-401 as we drive both programs toward meaningful clinical readouts in the second half of this year. We have also taken important steps to focus our financial resources on clinica...